Pregnancy There are no available human data during pregnancy to inform any drug-associated risks; however, systemic exposure to besifloxacin from ocular administration is low; oral administration of besifloxacin to pregnant rats during organogenesis or during pre/postnatal period did not produce adverse embryofetal or offspring effects at clinically relevant systemic exposures Lactation There are no data on presence of drug in human milk, effects on breastfed infant, or on milk production; however, systemic exposure to besifloxacin following topical ocular administration is low, and it is not known whether measurable levels of besifloxacin would be present in maternal milk following topical ocular administration The developmental and health benefits of breastfeeding should be considered, along with mother’s clinical need for therapy, and any potential adverse effects on breastfed infant from treatment